liu.seSearch for publications in DiVA
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Acute pulmonary vasoreactivity test with sildenafil or nitric monoxide before left ventricular assist device implantation
University of Tokyo, Japan .
University of Tokyo, Japan .
University of Tokyo, Japan .
University of Tokyo, Japan .ORCID-id: 0000-0002-4437-0260
Vise andre og tillknytning
2013 (engelsk)Inngår i: Journal of Artificial Organs, ISSN 1434-7229, E-ISSN 1619-0904, Vol. 16, nr 3, s. 389-392Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

There has been no established medical therapy to ameliorate pulmonary hypertension (PH) owing to left heart disease (LHD-PH). It has recently been shown that the left ventricular assist device (LVAD) can improve LHD-PH and therefore has the potential to become a major bridge tool for heart transplantation (HTx). However, some patients still have persistent PH even after LVAD treatment. It is essential to demonstrate the reversibility of end-organ dysfunction, including PH, prior to implantable LVAD treatment, especially in Japan, because implantable LVAD treatment is indicated only as bridge to transplantation. Here we report a patient with LHD-PH whose PH was demonstrated to be reversible by the acute pulmonary vasoreactivity test (APVT) with nitrogen monoxide (NO) and the phosphodiesterase-5 inhibitor sildenafil. Both inhaled NO and sildenafil reduced pulmonary vascular resistance, but pulmonary capillary wedge pressure was increased by NO, which was conversely decreased under increased cardiac output by sildenafil. After the patient was listed as an HTx recipient, pulmonary vascular resistance recovered down to an acceptable range with LVAD treatment. Based on these findings, we suggest that the APVT with sildenafil may be a useful and safe tool to predict improvement of PH after LVAD treatment.

sted, utgiver, år, opplag, sider
Springer Verlag (Germany) , 2013. Vol. 16, nr 3, s. 389-392
Emneord [en]
Heart failure; Transplantation; Pulmonary hypertension; Out of proportion
HSV kategori
Identifikatorer
URN: urn:nbn:se:liu:diva-111181DOI: 10.1007/s10047-013-0706-4ISI: 000325183500016PubMedID: 23559349OAI: oai:DiVA.org:liu-111181DiVA, id: diva2:754531
Tilgjengelig fra: 2014-10-10 Laget: 2014-10-10 Sist oppdatert: 2019-03-29

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fulltekstPubMed

Personposter BETA

Kato, Naoko

Søk i DiVA

Av forfatter/redaktør
Kato, Naoko
I samme tidsskrift
Journal of Artificial Organs

Søk utenfor DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 76 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf